News Website

Add-Back Therapy: Balancing Efficacy and Safety in Endometriosis - contemporaryobgyn.net

Add-Back Therapy: Balancing Efficacy and Safety in Endometriosis contemporaryobgyn.net

Published: Sept. 2, 2026, 12:05 p.m.

Read Full Article

Add-Back Therapy: Balancing Efficacy and Safety in Endometriosis - Contemporary OB/GYN

Add-Back Therapy: Balancing Efficacy and Safety in Endometriosis Contemporary OB/GYN

Published: Sept. 2, 2026, 12:05 p.m.

Read Full Article

Dr Silverstein on the Efficacy of Abemaciclib and Hormonal Therapy in Recurrent Ovarian and Endometrial Cancer - OncLive

Dr Silverstein on the Efficacy of Abemaciclib and Hormonal Therapy in Recurrent Ovarian and Endometrial Cancer OncLive

Published: Aug. 12, 2026, 3:24 a.m.

Read Full Article

BioNTech and DualityBio Report Clinically Meaningful Efficacy for Trastuzumab Pamirtecan in HER2-Expressing Endometrial Cancer - BioPharm International

BioNTech and DualityBio Report Clinically Meaningful Efficacy for Trastuzumab Pamirtecan in HER2-Expressing Endometrial Cancer BioPharm International

Published: April 15, 2026, 10:02 p.m.

Read Full Article

BioNTech, DualityBio tout 'clinically meaningful' efficacy for ADC in mid-stage endometrial cancer trial - BioSpace

BioNTech, DualityBio tout 'clinically meaningful' efficacy for ADC in mid-stage endometrial cancer trial BioSpace

Published: April 13, 2026, 5:57 p.m.

Read Full Article

Efficacy of Pamirtecan in HER2-Expressing Endometrial Cancer - OncLive

Efficacy of Pamirtecan in HER2-Expressing Endometrial Cancer OncLive

Published: April 12, 2026, 9:01 p.m.

Read Full Article

Mocertatug Rezetecan Displays Early Efficacy, Tolerability in PROC and Endometrial Cancer - OncLive

Mocertatug Rezetecan Displays Early Efficacy, Tolerability in PROC and Endometrial Cancer OncLive

Published: April 12, 2026, 6:25 p.m.

Read Full Article

Cadonilimab Plus Chemotherapy Shows Strong Efficacy and Safety in Advanced or Recurrent Endometrial Cancer - OncLive

Cadonilimab Plus Chemotherapy Shows Strong Efficacy and Safety in Advanced or Recurrent Endometrial Cancer OncLive

Published: April 12, 2026, 2:35 p.m.

Read Full Article

BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer - The Manila Times

BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer The Manila Times

Published: April 11, 2026, 11:01 a.m.

Read Full Article

ACR-368 in Serous Endometrial Cancer: Strong Phase 2b Efficacy, Manageable Safety, and a Clear Accelerated Approval Path Support Buy Rating on Acrivon - TipRanks

ACR-368 in Serous Endometrial Cancer: Strong Phase 2b Efficacy, Manageable Safety, and a Clear Accelerated Approval Path Support Buy Rating on Acrivon TipRanks

Published: Feb. 27, 2026, 7:47 p.m.

Read Full Article

Latest Articles

Add-Back Therapy: Balancing Efficacy and Safety in Endometriosis - contemporaryobgyn.net

Add-Back Therapy: Balancing Efficacy and Safety in Endometriosis - Contemporary OB/GYN

Dr Silverstein on the Efficacy of Abemaciclib and Hormonal Therapy in Recurrent Ovarian and Endometrial Cancer - OncLive

BioNTech and DualityBio Report Clinically Meaningful Efficacy for Trastuzumab Pamirtecan in HER2-Expressing Endometrial Cancer - BioPharm International

BioNTech, DualityBio tout 'clinically meaningful' efficacy for ADC in mid-stage endometrial cancer trial - BioSpace

Efficacy of Pamirtecan in HER2-Expressing Endometrial Cancer - OncLive

Mocertatug Rezetecan Displays Early Efficacy, Tolerability in PROC and Endometrial Cancer - OncLive

Cadonilimab Plus Chemotherapy Shows Strong Efficacy and Safety in Advanced or Recurrent Endometrial Cancer - OncLive

BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer - The Manila Times

ACR-368 in Serous Endometrial Cancer: Strong Phase 2b Efficacy, Manageable Safety, and a Clear Accelerated Approval Path Support Buy Rating on Acrivon - TipRanks

Subscribe to Our Newsletter